EW's TMTT sales may rise 57.1% in Q2, driven by global demand for PASCAL and EVOQUE systems. EW's TAVR revenue likely rose 5.2%, backed by U.S. and EU adoption of SAPIEN 3 Ultra RESILIA. EW's Surgical ...
JP Morgan upgraded Edwards Lifesciences (EW) to overweight from neutral highlighting accelerating growth in its transcatheter aortic valve replacement (TAVR) division and strength in its transcatheter ...
Edwards Lifesciences Corporation EW recently gained CE Mark for its PASCAL Precision transcatheter valve repair system used to treat mitral and tricuspid regurgitation. The PASCAL Precision system is ...
Edwards Lifesciences (EW Quick Quote EW - Free Report) , following the sell-off of the Critical Care wing, looks forward to developing the most comprehensive structural heart portfolio. In TMTT, the ...
Transcatheter Aortic Valve Replacement (TAVR) is projected to contribute $4.1 to $4.4 billion in 2025 sales, with constant currency growth of 5% to 7%. The Transcatheter Mitral and Tricuspid Therapies ...
Innovation with Purpose, Powered by Science, Centered on Patients: Edwards’ Commitment to Drive Value for the Healthcare Ecosystem IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results